Pharmaceutical
Health
Technology

Supernus Pharmaceuticals

$35.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-0.53%) Today
-$0.19 (-0.53%) Today

Why Robinhood?

You can buy or sell SUPN and other stocks, options, ETFs, and crypto commission-free!

About

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. Read More The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Employees
448
Headquarters
Rockville, Maryland
Founded
2005
Market Cap
1.87B
Price-Earnings Ratio
17.29
Dividend Yield
0.00
Average Volume
674.02K
High Today
$35.67
Low Today
$35.23
Open Price
$35.63
Volume
21.25K
52 Week High
$61.25
52 Week Low
$30.05

Collections

Pharmaceutical
Health
Technology
US
North America

News

Simply Wall StMar 15

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Is It A Smart Long Term Opportunity?

As Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings announcement on 31 December 2018, analysts seem cautiously bearish, with earnings expected to grow by 15% in the upcoming year compared with the higher past 5-year average growth rate of 64%. Currently with trailing-twelve-month earnings of US$111m, we can expect this to reach US$127m by 2020. Below is a brief commentary on the longer term outlook the market has for Supernus Pharmaceuticals. Investors wanting to learn more about other asp...

136
TradingNewsNowMar 7

Long or Short: Supernus Pharmaceuticals (NASDAQ: SUPN)

Supernus Pharmaceuticals trades as part of the healthcare sector and is part of the drug manufacturers industry. The company CEO is Jack Khattar. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Previous Intraday Trading Performance: The SUPN stock showed a previous change of -0.43% with an open at 37.59 and a close of ...

130
MarketBeatMar 3

Stock Price, News, & Analysis for Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial ...

1

Earnings

$0.24
$0.35
$0.46
$0.57
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.